Stay updated with breaking news from Initial Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Labrador Uranium Inc. (âLURâ, âLabrador Uraniumâ, or âthe Companyâ -
January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023
Get the latest information on Clinical Trials, FDA Drug Approvals, FDA Calendar, FDA Events and more on RTTNews
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The...
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...